These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19370395)

  • 1. Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer.
    Hess-Wilson JK
    Cancer Causes Control; 2009 Sep; 20(7):1029-37. PubMed ID: 19370395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
    Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
    Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear receptor profiling of bisphenol-A and its halogenated analogues.
    Delfosse V; Grimaldi M; le Maire A; Bourguet W; Balaguer P
    Vitam Horm; 2014; 94():229-51. PubMed ID: 24388193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells.
    Wetherill YB; Petre CE; Monk KR; Puga A; Knudsen KE
    Mol Cancer Ther; 2002 May; 1(7):515-24. PubMed ID: 12479269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver.
    Singh PB; Matanhelia SS; Martin FL
    Eur J Cancer; 2008 May; 44(7):928-36. PubMed ID: 18381236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling.
    Risbridger GP; Ellem SJ; McPherson SJ
    J Mol Endocrinol; 2007 Sep; 39(3):183-8. PubMed ID: 17766643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histopathologic changes due to combination of androgen deprivation and transurethral microwave thermotherapy in patients with localized prostate cancer].
    Suzuki R; Jujo Y; Koshiba K; Hoshiai O; Endo T; Aihara M; Nakajo H; Ohori M
    Hinyokika Kiyo; 2009 Feb; 55(2):79-85. PubMed ID: 19301612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphenol A in the aquatic environment and its endocrine-disruptive effects on aquatic organisms.
    Kang JH; Asai D; Katayama Y
    Crit Rev Toxicol; 2007; 37(7):607-25. PubMed ID: 17674214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine disrupting compounds and prostate cancer.
    Hess-Wilson JK; Knudsen KE
    Cancer Lett; 2006 Sep; 241(1):1-12. PubMed ID: 16298040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review. Current role and future perspectives of hyperthermia for prostate cancer treatment.
    Baronzio G; Gramaglia A; Fiorentini G
    In Vivo; 2009; 23(1):143-6. PubMed ID: 19368139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endocrine disruptor bisphenol A increases the expression of HSP70 and ecdysone receptor genes in the aquatic larvae of Chironomus riparius.
    Planelló R; Martínez-Guitarte JL; Morcillo G
    Chemosphere; 2008 May; 71(10):1870-6. PubMed ID: 18313723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphenol A: do recent studies of health effects among humans inform the long-standing debate?
    Dash C; Marcus M; Terry PD
    Mutat Res; 2006; 613(2-3):68-75. PubMed ID: 16757209
    [No Abstract]   [Full Text] [Related]  

  • 19. Relevance of steroid receptor measurements in the diagnosis and therapeutic management of cancer patients.
    Schwartz MK
    Prog Clin Biol Res; 1979; 33():201-8. PubMed ID: 531045
    [No Abstract]   [Full Text] [Related]  

  • 20. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer.
    Wetherill YB; Hess-Wilson JK; Comstock CE; Shah SA; Buncher CR; Sallans L; Limbach PA; Schwemberger S; Babcock GF; Knudsen KE
    Mol Cancer Ther; 2006 Dec; 5(12):3181-90. PubMed ID: 17172422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.